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Zhenglong Wu1†, Xiaona Huang2†, Xing Huang3, Qiang Zou4* and Yujiang Guo1,5*Abstract
Mir-29 microRNA families are involved in regulation of various types of cancers. Although Mir-29 was shown to play an
inhibitory role in tumorigenesis, the role of Mir-29 in breast cancer still remains obscure. In this study, we showed that
Mir-29a is the dominant isoform in its family in mammary cells and expression of Mir-29a was down-regulated in different
types of breast cancers. Furthermore, over-expression of Mir-29a resulted in significant slower growth of breast cancer cells
and caused higher percentage of cells at G0/G1 phase. Consistent with this over-expression data, knockdown of Mir-29a
in normal mammary cells lead to higher cell growth rate, and higher percentage of cells entering S phase. We further
found that Mir-29a negatively regulated expression of B-Myb, which is a transcription factor associated with tumorigenesis.
The protein levels of Cyclin A2 and D1 are consistent with the protein level of B-Myb. Taken together, our data suggests
Mir-29a plays an important role in inhibiting growth of breast cancer cells and arresting cells at G0/G1 phase. Our data
also suggests that Mir-29a may suppress tumor growth through down-regulating B-Myb.
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Breast cancer is the most common cancer diagnosed in
women. Although there were noteworthy advances in the
early diagnosis and treatment during the past several de-
cades, breast cancer still stands as the leading cause of
cancer death in women worldwide [1,2]. The underlying
mechanism for breast cancer development and metastasis
is far from being completely understood. The high preva-
lence of this disease calls for more mechanistic insights for
the development of new generation diagnostic and thera-
peutic strategies. Recently (after 2005), there is a growing
interest in the roles of a new class of small non-coding
RNAs, microRNAs (miRNAs) in breast cancer develop-
ment [3,4].
MicroRNAs are ubiquitously expressed small RNAs
which exert negative regulatory effects on gene expres-
sion at a post-transcriptional level [5]. Given the fact
that microRNAs theoretically target any mRNA, it is* Correspondence: zqhsyy@sohu.com; guoyujiang158@163.com
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reproduction in any medium, provided the orlikely that microRNAs possess a very broad functional
spectrum which includes cell cycle regulation, cell growth,
apoptosis, cell differentiation and stress response [5-9].
Consistent with this notion, it is no surprise that micro-
RNAs are extensively involved in human cancer develop-
ment [10]. To date, there are over 1000 miRNAs that have
been discovered in human, among which MiR-29 stands
as one of the most intriguing miRNA families which may
play pivotal roles in cancer biology [8,11].
Composed of three mature members (MiR-29a, b and c),
this family has been shown to be down-regulated in many
different types of cancers and have been attributed pre-
dominantly tumor-suppressing properties. In lung cancers,
MiR-29 family was reported to regulate specific genes asso-
ciated with tissue invasion and metastasis in lung adeno-
carcinoma [8]. In hematologic neoplasms, MiRNA-29
expression levels are inversely correlated with prognosis of
Mantle cell lymphoma (MCL) [12]. In addition, MiR-29
reduces cell growth and induces apoptosis in primary acute
myeloid leukemia (AML) cells and related cell lines [13].
Moreover, it has been reported that by inhibiting MMP2
activity, MiR-29 plays an important inhibitory role in APO-
BEC3G induced colon cancer migration and invasion [14].
Finally, consistent with the data from studies on other
types of cancer, MiR-29 family inhibits ovarian cancer. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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3B [15].
Unfortunately, there is relatively lack of information
on the role of MiR-29 in breast cancer. Study from JK
Richer’s group demonstrated that Mir-29a has an inhibi-
tory role in tumor growth in vivo [16]. However, in another
paper, the authors showed that MiR-29a may promote
metastasis through facilitating epithelial-to-mesenchymal
transition [17]. Thus, the function of Mir-29 in tumorigen-
esis and metastasis of breast cancer still remains unclear.
In the current study, we are endeavored to further eluci-
date the roles of MiR-29 in breast cancers, which highlights
MiR-29 as a potential new biomarker and therapeutic
target for breast cancer.
Materials and methods
Reagents
Micro-RNA assays for mir-29a (002112), mir-29b (000413),
mir-29c (000587) and RUN48 (001006) were purchased
from Applied Biosystems. Fetal bovine serum (FBS) was
from GIBCO. SuperSignal Substrate Western blotting
detection system was from Pierce (USA). PVDF mem-
brane was purchased from Bio-Rad Inc. B-Myb antibody
(05–175) and cyclin D1 antibody were purchased from
Millipore. Cyclin A2 (ab32498) antibody and GAPDH
antibody (ab9485) were purchased from Abcam. Luciferase
Assay Kit and pMIR-REPORT System were purchased
from Applied Biosystems. β-Gal Assay Kit was purchased
from Invitrogen (K1455-01). Lipofectamine 2000 reagent
was purchased from Invitrogen.
Cell culture
T-47D, MDA-MB-453, MCF-7 and MCF-10A cells were
obtained from American Type Culture Collection. Human
Mammary Epithelial Cells (HMEC) were purchased from
Invitrogen (A10565). Cells were maintained in their proper
media recommended by the companies and placed in a
humidified incubator with 5% CO2 and 95% air at 37°C.
Plasmids and transduction
A DNA fragment containing the hsa-miR-29a precursor
(plus 100 bp upstream and 100 bp downstream) was amp-
lified from genomic DNA of HMEC cells and cloned into
pcDNA(+)3.1 vector (Invitrogen). The primers used here
are: 5′-gaattcactcattccattgtgcctgg-3′ and 5′-ctcgagttgctttg
catttgttttct-3′.
MiRZip-29a construct (MZIP29a-PA-1) and its vector
control (SI505A-1) were obtained from System Biosciences.
For the luciferase assay, pMIR-REPORT System (Applied
Biosystems) was used. The plasmids (pMIR-REPORT-
Luciferase-B-Myb-3′-UTR and its mutant) were constructed
by following methodology. A 363-bp fragment (nt 2319–
2681) of the 3′UTR of B-Myb (NM_002466.2) containing
the miR-29a binding site was cloned into the pMIR-REPORT-Luciferase vector between HindIII and SacI
sites. This fragment was amplified by PCR using the
primers: gcgcaagcttggtgttgagggtgtcacgag and gcgcgagctc
tgcaccaagagagggtgagc. QuikChange Site-Directed Muta-
genesis Kit (Stratagene) was used to generate pMIR-
REPORT-Luciferase-B-Myb-3′-UTR-mutant plasmid by
using following primers: 5′-ggctcctgagattaacaacaaa-3′
and 5′-tttgttgttaatctcaggagcc-3′. A plasmid coding β-
galactosidase (pMIR-REPORT β-gal control) was used
to normalize variability due to differences in cell viabil-
ity and transfection efficiency.
Cell transfection
MDA-MB-453 cells were transfected with vector or plas-
mid encoding hsa-miR-29a precursor by using lipofecta-
mine 2000. After drug-selection (0.5 mg/ml G418 for 7
days), cells were used in different experiments. Transfec-
tion of MDA-MB-453 cells for luciferase assay is de-
scribed in detail below.
Packaging of pseudoviral particles and transduction of
the target cells
MiRZip-29a plasmid or its vector control was trans-
fected into 293TN cells and pseudoviral particles were
collected following the provider’s protocol. Pseudoviral
particles were applied on MCF-10A cells. 24 hours later,
cells were subjected to drug selection (1 μg/ml puro-
mycin) for 3 days. After drug-selection, cells were used
in different experiments.
Luciferase assay
To directly evaluate the effect of mir-29a on B-Myb, we
used the luciferase assay. MDA-MB-453 cells were first
transfected with vector or plasmid encoding hsa-miR-29a
precursor. After drug-selection, cells were transfected with
pMIR-REPORT-Luciferase-B-Myb-3′-UTR or its mutant
using lipofectamine 2000. A plasmid encoding beta-galac
tosidase (pMIR-REPORT β-gal) was co-transfected with
these plasmids. 48 hours later, luciferase activity was mea-
sured by using Luciferase Assay Kit following the manu-
factory protocol. Beta-galactosidase activity was measured
by using β-Gal Assay Kit. The luciferase activity was
normalized against the β-Gal activity from the same cells.
Western blot
Proteins extracted from different cells were subjected to
electrophoresis on a polyacrylamide gel and then trans-
ferred onto PVDF membranes. After that, membranes
were blocked with 5% fat free dry milk in TBS-T for 1 h.
The primary antibodies were applied on the membranes
at 4°C overnight before they were washed out by TBS-T.
The membranes were then incubated with secondary
antibodies for 1 h at room temperature in TBS-T. After
four washes in TBS-T, chemiluminescent substrate (Pierce,
Wu et al. Journal of Experimental & Clinical Cancer Research 2013, 32:98 Page 3 of 7
http://www.jeccr.com/content/32/1/98USA) was applied onto the membranes and the films were
processed in a dark room.
TaqMan miRNA analysis
The experiments were carried out following the manu-
factory protocol. Briefly, for RT reactions, 10 ng of total
RNA was used in each reaction and mixed with the
miRNA-specific RT primer. The thermal cyclers are as
following: 16°C for 30 min, 42°C for 30 min, 85°C for 5
min. After the RT reaction, the products were diluted at
1:15, and 1.33 μl of the diluted RT-product was used for
PCR reaction with specific primers. The thermal cyclers
are as following: 95°C for 10 min, 95°C for 15 sec, 60°C for
60 sec, 40 cycles. The real-time PCR results were analyzed
by using CT values. RUN48 was used for normalization.
Guava assay
The experiments were carried out following the manu-
facture’s protocol. Briefly, cells were cultured in 6-well
plates and harvested using standard protocols. Then cells
were washed once with ice-cold PBS, fixed with 70% etha-
nol (−20°C) and stored at 4°C. Then the ethanol was re-
moved and the cells were washed once with ice-cold PBS
before staining. Finally, 200 μl Guava Cell Cycle reagent
was used to resuspend about 2 × 105 cells and cells were
transferred to 96-well plates for data acquirement.
Results
Mir-29a is the dominant member of mir-29 family
Mir-29 family is composed of three members Mir-29a, b
and c, which are involved in tumorigenesis, chronic lym-
phocyte leukemia, acute myeloid leukemia and apoptosis
[13,18]. In order to detect relative levels of three iso-
forms of Mir-29 family, Taqman MicroRNA assays were
performed in MCF-10A and HMEC cells (Figure 1A and
1B). In both MCF-10A and HMEC cells, the expression
levels of Mir-29a are significantly higher than the other
two isoforms, indicating Mir-29a may play a more im-
portant role than the others. Because Mir-29a is the
dominant isoform of Mir-29 family in mammary cells
(>65% of total Mir-29 expression), and also due to the
high similarity among three isoforms (Figure 1C), thus
the following study mainly focuses on Mir-29a.
Expression levels of Mir-29a are significantly lower in
breast cancer cells when compared to those in normal
mammary cells
Previous studies have showed that Mir-29 isoforms are
involved in suppression of tumorigenesis [3,15,19-21].
Thus it is reasonable to hypothesize that expression
of Mir-29a is altered in breast cancer cells, and over-
expression of Mir-29a may suppress breast cancer cell
growth. To test the hypothesis, expression levels of Mir-29a
were assessed in normal human mammary epithelialcells (HMEC), immortalized normal breast epithelia (MCF-
10A) and breast cancer cells (MDA-MB453, T47D and
MCF-7) (Figure 2). As shown in Figure 2, expression levels
of Mir-29a were significantly lower in breast cancer cells.
Expression levels of Mir-29a decreased approximately by
83% in T47D cells, 68% in MDA-MB-453 and 33% in
MCF-7 cells compared to expression level of Mir-29a in
MCF-10A cells. The down-regulated expression level of
Mir-29a in various breast cancer cell lines strongly suggests
that Mir-29a is inhibitory to cancer cells.
Over-expression of Mir-29a inhibits growth of MDA-MB-
453 cells
To further study whether Mir-29a negatively regulates
cancer cell growth, Mir-29a was over-expressed in MDA-
MB-453 cells. As shown in Figure 3A, Mir-29a expression
level was 5.6-fold higher in cells transduced with Mir-29a
over-expression construct than vector control. MDA-MB-
453 cells over-expressed with Mir-29a displayed signifi-
cantly slower growth rate than control cells (Figure 3B).
To further determine if slower cell growth rate was due to
perturbation of cell cycles progression, cell cycle profile
was investigated by monitoring cell numbers at different
stages (Figure 3C-E). Interestingly, compared to vector
control, over-expression of Mir-29a caused 15% (P < 0.01)
more cells to stay at G0/G1 phase (Figure 3E). This data
suggested that over-expression of Mir-29 resulted in the
arrest of cell cycle in G0/G1 phase and prevention of cells
from entering into the S phase.
Mir-29a knockdown facilitates growth of MCF-10A cells
To confirm the inhibitory role of Mir-29a, cell growth and
cell cycle profile were investigated in MCF-10A cells with
Mir-29a knockdown. Suppression of Mir-29a resulted in a
higher cell growth rate than empty vector control (Figure 4A
and 4B). In MCF-10A cells with knockdown of Mir-29a,
the percentage of cells at G0/G1 phase was 12% (P < 0.01)
lower than that in control cells (Figure 4C-E). This data
suggested that knockdown of Mir-29a in normal cells
caused more cells entering to S phase and thus promote
cell growth. These results, together with data of over-
expression of Mir29a in breast cancer cells, strongly sug-
gested Mir-29a participates in arresting cells at G0/G1
phase and thus inhibiting tumor cell growth.
Mir-29a negatively regulates cell growth through its
depression on B-Myb expression
The next question is how Mir-29a inhibits growth of
cells. To further investigate this question, we searched
the literature and found Mir-29a might inhibit growth of
cells by down-regulating the transcription factor, B-Myb
[22]. To evaluate the direct effect of mir-29a on B-Myb
expression, we used pMIR-REPORT System. A fragment
representing 3′-UTR of B-Myb was cloned into the 3′
Figure 1 The relative levels of mir29 isoforms in mammary epithelial cells. A, the relative levels of mir29 isoforms in MCF-10A, n = 5, Mean ± SD.
B, the relative levels of mir29 isoforms in HMEC, n = 5, Mean ± SD. C, the comparison of mir29 isoforms.
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in mir-29a over-expressed cells, the expression of lucifer-
ase was dramatically inhibited (P < 0.01). In contrast with
inhibition of mir-29a on wild type 3′-UTR of B-Myb, mir-
29a cannot inhibit the luciferase expression (P > 0.05),Figure 2 Relative levels of mir-29a in normal mammary epithelia and
against that level in MCF-10A cells, n = 5, Mean ± SD.when the binding site of mir-29a in 3′-UTR of B-Myb was
mutated. Consistent with this, in MDA-MB-453 cells that
over-expressed Mir-29a, protein level of B-Myb decreased
(Figure 5C). Consistently in these cells, the downstream
effectors of B-Myb such as Cyclin A2 and D1 were alsobreast cancer cells. Here relative levels of mir-29a were normalized
Figure 3 Over-expression of miR-29a in MDA-MB-453 cells inhibits growth of cells. A, relative levels of mir-29a in cells with or without mir-29a
over-expression, n = 5, Mean ± SD. B, the growth curve of above cells, n = 5, Mean ± SD. C and D, representative figures of cell cycle analysis using
Guava assay. E, quantitative analysis of the results of cell cycle examination, n = 5, Mean ± SD.
Figure 4 Knockdown of miR-29a in MCF-10A cells increases growth of cells. A, relative levels of mir-29a in cells with or without mir-29a
knockdown, n = 5, Mean ± SD. B, the growth curve of above cells, n = 5, Mean ± SD. C and D, representative figures of cell cycle analysis using
Guava assay. E, quantitative analysis of the results of cell cycle examination, n = 5, Mean ± SD.
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Figure 5 B-Myb acts as the downstream effector of mir-29a to regulate cell cycle. A, the scheme of the plasmid construction for the
luciferase assay. B, relative luciferase activities of the cells (with or without mir-29a over-expression) transfected with either wild or mutant 3′-UTR
of B-Myb; n = 5, Mean ± SD. C, protein levels of cyclin A2, cyclin D1 and B-Myb in MDA-MB-453 cells with or without mir-29a over-expression.
D, protein levels of cyclin A2, cyclin D1 and B-Myb in MCF-10A cells with or without mir-29a knockdown.
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On the contrary, in MCF-10A cells with Mir-29a knock-
down, the protein level of B-Myb is dramatically up-
regulated (Figure 5D). Consistent with an increased level
of B-Myb, in MCF-10A cells, levels of Cyclin A2 and D1
were also up-regulated. All these findings suggested that
Mir-29a probably regulates cell growth through B-Myb.
Discussion
As described earlier, the function of Mir-29a in tumori-
genesis and metastasis remains controversial. Muniyappa
et al. showed that Mir-29a was down-regulated in invasive
lung cancer cells and invasive phenotype of cancer cells
could be suppressed by ectopic expression of Mir-29a [23].
Study from Xu et al. also showed that expression level ofMir-29a is significantly lower in various solid tumors [24].
In contrast, Mir-29a is also shown to be up-regulated in
certain leukemia cells [25]. In this study, we focused on
the role of Mir-29a in breast cancers cells. We showed that
expression level of Mir-29a is down-regulated in various
breast cancer cells (Figure 2). This data indicates that Mir-
29a expression is probably associated with breast cancer.
One piece of evidence to support this hypothesis is that
over-expression of Mir-29a in breast cancer cells signifi-
cantly reduce cancer cell growth rate (Figure 3B). Consis-
tent with this result, knockdown of Mir-29a in normal
mammary epithelial cells cause higher cell growth rate
(Figure 4B). These data strongly suggested Mir-29a inhib-
ited tumorigeneses through suppression of cell growth.
We also showed that the inhibitory effect of Mir-29a to
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cells in G0/G1 cells (Figure 3C-E and 4C-E). Previous
studies showed that Mir-29a is able to suppress the ex-
pression of tristetraprolin, which is involved in epithelial-
to-mesenchymal transition [17]. A study also showed that
Mir-29a targets protein P42.3, which was also found, asso-
ciated with tumorigenicity [26]. In this study, we showed
that Mir-29a negatively regulated expression of B-Myb
(Figure 5), which is a transcription factor broadly involved
in regulating cell cycle and apoptosis and probably is a
promoting factor for cancer [27]. Downstream effectors of
B-Myb, such as Cyclin A2 and D1, were also correspond-
ingly regulated by Mir-29a. Cyclin D1 is one of highly
over-expressed proteins in breast cancer cells and over-
expression of Cyclin D1 protein was found in 40-90% of
cases of invasive breast cancer [28]. Cyclin A2 is involved
in S phase and G2-M phase transition and is also over-
expressed in various cancers [29-31]. Taken together, in
current paper, we showed that Mir-29a may act as a tumor
suppressor through its inhibitory function on growth of
breast cancer cells, and down-regulating expression of
B-Myb by Mir-29a may contribute to this process.
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